Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azithromycin
Drug ID BADD_D00203
Description Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration [A174172]. It was initially approved by the FDA in 1991 [A174175]. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin [A174169]. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides [A174175]. In March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug [hydroxychloroquine]. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.[A192546]
Indications and Usage For the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions: H. influenzae, M. catarrhalis, S. pneumoniae, C. pneumoniae, M. pneumoniae, S. pyogenes, S. aureus, S. agal
Marketing Status Prescription; Discontinued
ATC Code J01FA10; S01AA26
DrugBank ID DB00207
KEGG ID D06390
MeSH ID D017963
PubChem ID 447043
TTD Drug ID D03HJK
NDC Product Code 53002-0470; 50111-787; 68071-2672; 70710-1458; 53002-5228; 68071-4795; 0781-5789; 68788-8125; 70518-2708; 50090-4720; 71610-001; 0409-0144; 50090-2509; 62332-251; 63629-8034; 68071-1528; 63629-7784; 63629-8251; 50090-4458; 68071-4773; 59651-008; 16571-695; 42806-147; 70710-1457; 59762-3051; 55150-174; 68788-7659; 71205-196; 50090-4721; 70518-0713; 68071-4902; 55700-731; 65862-641; 24658-706; 72189-314; 70518-2562; 50090-5376; 68071-4785; 63187-189; 76420-006; 0093-2027; 0781-5793; 53002-6221; 68071-4786; 53002-2230; 70518-3217; 71205-158; 70771-1424; 68071-4711; 71205-503; 50090-5283; 42291-082; 64679-961; 71205-645; 63187-169; 63187-594; 64679-964; 68788-8124; 65862-642; 42291-084; 55695-002; 71205-253; 70518-2433; 68788-7549; 68071-2507; 76420-213; 71205-519; 53002-2228; 68788-7066; 68071-4779; 63187-093; 63629-8311; 61294-9990; 59762-3130; 69306-250; 68071-4364; 42291-083; 0781-8089; 71610-381; 61919-555; 59651-007; 68071-2543; 53002-2225; 50090-5366; 68071-5035; 42806-151; 50111-788; 62332-253; 46708-253; 69452-173; 64679-962; 59762-3140; 70518-3254; 68071-2297; 45865-536; 60760-502; 68788-7598; 50090-0984; 63187-007; 59762-3120; 68071-5058; 68071-4812; 71335-1755; 69452-172; 71205-216; 68071-1527; 68788-7307; 68071-4774; 53002-2231; 68788-7507; 63187-622; 0093-2026; 71205-021; 50090-0983; 60760-808; 68071-5238; 43386-471; 42806-149; 71335-1252; 16571-696; 70710-1460; 50111-789; 53002-2224; 71205-424; 62756-512; 24658-708; 72189-088; 38779-2246; 59762-2198; 72189-087; 68071-5082; 59762-3110; 70518-0784; 55700-784; 42806-150; 69452-171; 50090-2491; 72189-093; 55700-852; 70710-1459; 0781-8090; 0781-8091; 68071-2266; 70771-1425; 46708-058; 53002-5221; 70518-3169; 70771-1422; 70518-0599; 53002-0473; 70771-1423; 65427-310; 68071-5170; 68071-2622; 53002-0472; 68071-2529; 71335-1195; 62332-252; 72189-015; 68788-7636; 63187-604; 68071-4255; 68071-4976; 46708-057; 55695-003; 71205-566; 43386-470
Synonyms Azithromycin | Azythromycin | Sumamed | Toraseptol | Vinzam | CP-62993 | CP 62993 | CP62993 | Zithromax | Azitrocin | Azadose | Ultreon | Zitromax | Azithromycin Dihydrate | Dihydrate, Azithromycin | Azithromycin Monohydrate | Monohydrate, Azithromycin | Goxal | Zentavion
Chemical Information
Molecular Formula C38H72N2O12
CAS Registry Number 83905-01-5
SMILES CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C) C)O)(C)O)C)C)C)O)(C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Visual acuity reduced17.17.01.011; 06.02.03.0010.000025%
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.0030.000644%
Weight decreased13.15.01.005--
Wheezing22.03.01.0090.000025%
White blood cell count increased13.01.06.013--Not Available
Tubulointerstitial nephritis20.05.02.002--Not Available
Hypoacusis04.02.01.006--
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Emotional distress19.04.02.008--Not Available
Red blood cell sedimentation rate increased13.01.03.0010.000025%Not Available
Abasia17.02.05.035; 08.01.02.0070.000025%Not Available
Blood phosphorus increased13.11.01.016--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Generalised erythema23.03.06.0080.000025%Not Available
Platelet count increased13.01.04.002--Not Available
Eye pruritus06.04.05.0060.000076%Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal stiffness15.03.01.005--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Transaminases increased13.03.01.0150.000038%Not Available
Infusion site reaction12.07.05.006; 08.02.05.005--Not Available
Haemorrhage24.07.01.002--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Hepatic enzyme increased13.03.01.0190.000050%Not Available
Sinusitis bacterial22.07.04.003; 11.02.01.032--Not Available
Cardiac disorder02.01.01.003--Not Available
Eyelid disorder23.03.03.028; 06.08.03.0100.000025%Not Available
Infestation23.09.05.001; 11.09.01.001--Not Available
Inflammation08.01.05.007--Not Available
The 11th Page    First    Pre   11 12    Next   Last    Total 12 Pages